JOINT CERS AND KRS RETIREE HEALTH PLAN COMMITTEE May 19, 2022, 10:00 a.m. ET (9:00 a.m. CT) Live Videoconference/Facebook Live Agenda

- 1. Call to Order Jerry Powell
- 2. Roll Call Sherry Rankin
- 3. Public Comment Sherry Rankin
- 4. Vice-Chair Election* Jerry Powell
- 5. Approval of Committee Minutes February 10, 2022* Jerry Powell
- 6. Kentucky Teachers Retirement Systems (TRS) Presentation Jane Gilbert
 - a. Pharmacogenomics at TRS
- 7. Account Management Review Humana Tracey Garrison
 - a. 2021 Plan Performance
 - i. Overview by Plan and Trust
 - ii. Dental Utilization
 - iii. KPPA Stars Score
 - b. McClennan Pilot Program Results
 - c. Pharmacogenomics
- 8. Other Business:
 - a. KPPA Medicare Advantage Request For Proposal (RFP) update Connie Pettyjohn
- 9. Adjourn *Jerry Powell*

^{*}Board Action Required

KENTUCKY PUBLIC PENSIONS AUTHORITY JOINT CERS-KRS BOARD OF TRUSTEES RETIREE HEALTH PLAN COMMITTEE MEETING FEBRUARY 10, 2022 at 10:00 A.M., E.D.T. VIA LIVE VIDEO TELECONFERENCE

At the February 10, 2022 meeting of the Retiree Health Plan Committee of the Joint CERS and KRS Board of Trustees, the following Committee members were present: CERS – Jerry Powell, Chair and JT Fulkerson; KRS – Larry Totten. KPPA Staff members present were Erin Surratt, Rebecca Adkins, Connie Pettyjohn, Vicki Hale, Abby Sutherland, Brian Towles, Shaun Case, Glenna Frasher, Ashley Gabbard and Sherry Rankin. Others in attendance included CERS CEO Ed Owens III and Tracy Garrison, Larry Loew, Carrie Lovell, Dianna Cunningham, and Brandon Steinbrook from Humana.

Mr. Powell, Committee Chair, called the meeting to order.

Ms. Hale read the Legal Public Statement.

Ms. Rankin called roll.

There being no public comment, Mr. Powell introduced the agenda item *Approval of Committee Minutes-November 9, 2021*. Mr. Fulkerson made a motion and Mr. Totten seconded to approve the minutes as presented. The motion passed unanimously.

Mr. Powell introduced the agenda item *Account Management 2021 Review - Humana Presentation*. Ms. Tracy Garrison with Humana stated that today's presentation would be a review of the 2021 Account Management. Ms. Garrison reviewed the Member Engagement report which included six (6) live online enrollment events in October with a total of 170 participants, six (6) live online educational events with a total of 29 participants, and 592 views of the annual enrollment education video which is accessible through the KPPA website.

Ms. Garrison continued with a review of the Call Center Report for 2021 which showed a total of 63,125 calls from KPPA members. She reviewed the other call metrics that are tracked for all calls coming from KPPA members. She indicated that the top three call drivers for the 2021 benefit year included questions regarding Benefits, Claims, and Pharmacy.

Ms. Garrison stated that Humana focuses on Member Satisfaction. She reviewed data regarding the number of surveys and the Net Promotor Scores over the 2021 calendar year. The Net Promotor Score for transactional satisfaction, which results were based on surveys conducted immediately after the ending of a call which came into the call center, was 61.97. Ms. Garrison reviewed the Overall Satisfaction rate of 90% for 2021, which was a decrease from the 95% rate for 2020. She stated that the 2020 rate may have been a little elevated due to COVID and the activities surrounding COVID, but historically the satisfaction rates have been 90% or higher for KPPA. Ms. Garrison indicated that a full copy of the survey, including the summary of the results, would be sent to Connie Pettyjohn should anyone be interested in the full report. Ms. Garrison reviewed the satisfaction rates for Time on Hold While Representative Researched Question, Representative Took Responsibility for Getting Answers, Knowledgeable Representative, and Caring Representative. She indicated that these ratings are reflective of the changes Humana has made internally to improve services.

Ms. Garrison introduced Dianna Cunningham who discussed information on the provider network. Ms. Cunningham reviewed the Humana Value-based Continuum, which is a broad spectrum program where Humana can provide financial rewards to primary care providers for improving quality in outcomes and costs. She reviewed the Non-Value Based, Value-Based: Upside Only, and Value-Based: Downside Risk including the financial opportunity and risk associated with each program. Ms. Cunningham then discussed the various programs available to the providers including the Population Insights Compass which provides the value-based providers with a platform for health insights and analytics. She indicated that Humana also has a Provider Engagement Team to support the value-based providers as they transition to value-based care. She discussed the Care

Decision Insights program that is used to increase quality and value to the value-based providers. Ms. Cunningham discussed the Electronic Medical Record Interoperability, which is essentially data exchange between provider groups and Humana for the purposes of improving quality, increasing satisfaction for providers and patients, and reducing administrative burden.

Ms. Garrison introduced Brandon Steinbrook who reviewed Humana's differentiated provider network and partnerships drive better patient outcomes and lower costs for KPPA retirees. He stated that Humana is the number one (1) provider network across all payers with 100% of Kentucky facilities contracted and participating in-network with Humana. He reported that 54% of Humana's Group members in Kentucky use a Primary Care Physician that partner with Humana to deliver value-based care, aligning financial incentives to reduce cost and improve health outcomes. He stated that there are 42 unique provider groups in Kentucky that participate in value-based care with retired members. He announced that there are seven (7) new value-based physician offices bringing best-in-class performance to the retired members in the Louisville area as of the 2022 plan year.

Mr. Powell introduced the agenda item *Other Business*. Ms. Pettyjohn discussed a mistake that was presented in the Premium Amount for the MA Mirror PDP Essential/Premium Plan that was presented to the Committee in the September 2021 meeting. The premium amounts of \$36.45 for the PDP Essential for 2022 and \$136.30 for the PDP Premium for 2022 were previously approved by the Boards. Ms. Pettyjohn reported that those premium amounts have been lowered to \$36.18 for the PDP Essential for 2022 and to \$135.31 for the PDP Premium for 2022.

There being no further business, a motion to adjourn was made by Mr. Fulkerson and seconded by Mr. Totten, the meeting adjourned.

The remainder of this page intentionally left blank

CERTIFICATION

| I hereby certify that I was present at this meeting the Committee on the various items considered to all requirements of KRS 61.805-61.850 were me | by it at this meeting. Further, I certify that |
|--|--|
| - | Recording Secretary |
| I, Jerry Powell, the Chair of the Joint Retiree | Health Plan Committee of the Board of |
| Trustees of the County Employees Retiremer Systems, do hereby certify that the Minutes of th approved by the Joint Retiree Health Plan Comm | ne meeting held on February 10, 2022 were |
| | Committee Chair |
| I have reviewed the Minutes of the February 10, meeting for form, content and legality. | 2022 Joint Retiree Health Plan Committee |
| | Executive Director |
| | Office of Legal Services |



Teachers' Retirement System of the State of Kentucky



If a medication is unsafe or won't work for you, wouldn't you want to know?



KEHP MEHP

Personalized Medicine

One Retiree's Story

I am *so grateful* for the information that was given to me and my physician. I was taking metropolol for my *heart condition*. Your tests showed that it *stayed too long in my system*. I sometimes had the feeling that I was on the verge of *fainting*. I *had not had that feeling since I started taking the new suggested medication*. I thank you from the bottom of my heart.

- Member, Teachers' Retirement System of the State of Kentucky

Medication: Expense and Risk





Prescription drug spending has exceeded \$300 billion a year since 2015.1



Adverse drug events account for nearly 700,000 emergency department visits and 100,000 hospitalizations a year.³



Medication errors occur in 3.8 million inpatient admissions and 3.3 million outpatient visits.²



There are 275,689 deaths a year attributable to medication errors.⁴

^{1. &}quot;A Look at Drug Spending in the U.S.," Pew Charitable Trust, 28 Aug. 2018. https://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2018/02/a-look-at-drug-spending-in-the-us. Accessed 18 Feb 2020.

^{2. &}quot;Preventing Medication Errors: A \$21 Billion Opportunity," Network for Excellence in Health Innovation, 2011. https://www.nehi.net/bendthecurve/sup/documents/Medication_Errors_%20Brief.pdf. Accessed 18 Feb 2020.

^{3. &}quot;Medication Errors and Adverse Drug Events," US Health and Human Services, Sept 2019. https://psnet.ahrq.gov/primer/medication-errors-and-adverse-drug-events. Accessed 18 Feb 2020.

^{4.} Watanabe J, et al, "Cost of Prescription Drug-Related Morbidity and Mortality," Ann Pharmacother. 2018 Sep;52(9):829-837

Your DNA Really Matters

CORIELL.


Pharmacogenomics (PGx)


Using DNA to see what drugs will be safe and effective





Why Most Drugs Only Work in Some Patients





27% of the U.S. population cannot metabolize Clopidogrel

Codeine has little effect on as much as 20% of the population

Even everyday drugs, such as Advil and Tylenol, can have widely varying effects

DNA Testing is NOT Sufficient



CLS' Personalized Medicine Program

brings together rigorously-vetted genetic guidance with **dozens of other factors** of patient-specific prescribing risk.

Healthcare providers are **empowered with answers** rather than research materials.

Real-time modeling allows pharmacists and doctors to see the results of medication changes **before they experiment** with them on their patients.



The Teachers' Retirement System of the State of Kentucky will reduce healthcare costs by implementing a program focused on improving medication safety and efficacy for its members.

The program will utilize genetic testing and personalized therapy analysis delivered to physicians through expert pharmacist consultation.

CORIELL

TRS Program Overview



Mission & Goals From Program Kickoff



Provide a 'zero disruption' implementation.



Achieve 5-star feedback from participant members.



Demonstrate a 3x return on program investment over 3 years.



Be perceived as fiscally responsible, ethically motivated, and medically innovative by all stakeholders.



Become a national example of progressive, creative, and innovative leadership in pension fund healthcare management.

DENTIAL + Coriell Life Sciences + www.coriell.com

Program Components



The Personalized Medicine Program is a turnkey solution that combines genetic testing with expert pharmacy review to provide what physicians really need – credible and immediately actionable treatment guidance.



Population Analytics

"Will this program provide benefit for our members?"



Member Engagement

Fully-coordinated education and enrollment



Genetic Testing

Cost-effective, comprehensive DNA testing by CLIAlicensed laboratories



Pharmacy MTM Review


Clear, actionable recommendations via Medication Action Plan (MAP)

Case Study: Pre-Program Population Analytics



36,000 retirees aged 65 to 109

Using de-identified claims information, CLS provided the TRS pension fund with an in-depth analysis of the potential return on investment with the program.





15 Average # of prescriptions



75% Had high BP/heart disease



58% Had high cholesterol



50% Had pain/inflammation

CONFIDENTIAL • Coriell Life Sciences • www.coriell.com

Program Overview—Pre-Program Population Analytics












POPULATION ANALTICS

MEMBER ENGAGEMENT

GENETIC TESTING

PHARMACY MTM REVIEW




% of Patients taking meds that have known PGx implications

CONFIDENTIAL • Coriell Life Sciences • www.coriell.com

Program Overview







GENETIC TESTING



CORIELL.


PHARMACY MTM REVIEW

POPULATION ANALTICS









Pharmacist Review & Report







MEMBER ENGAGEMENT



GENETIC TESTING





PHARMACY MTM REVIEW

CLS proprietary software, **GeneDose LIVE™** allows teams of pharmacists and physicians to review the genetic and non-genetic concerns for individual patients and **quickly shows which alternatives would be best suited**.





The MAP document provides a **clear and concise** way for the pharmacist to **communicate the updated plan** to the prescriber.

KEHP

MEHP


Know Your Rx Coalition

Free counseling with live pharmacists

Know Your Rx Coalition *Pharm-Assist*

Hours: Monday to Friday, 8 a.m. to 6 p.m. ET

Phone: 855-218-5979 Email: KYRx@uky.edu Website: www.KYRx.org







MEHP

Personalized Medicine




TRS Solution: Personalized Medicine Partnership



This personalized medicine program uses DNA testing to help you find out if your medications work for you.

You Your Doctor Your Pharmacist







MEHP enrollees can contact Coriell at 888-454-9024 or online at www.coriell.com/trs to request a free DNA kit.

Non-Medicare KEHP enrollees are eligible for the DNA kit

Pay through credit card or your

CDHP HRA



KEHP MEHP

Personalized Medicine

How it Can Help

Your DNA matters

Using DNA to see what drugs will be safe and effective — Pharmacogenomics

Steps

Collect genetic information
Empower pharmacists
Communicate the Medication Action Plan






Personalized Medicine

Why It Works

- Helps avoid taking ineffective medications that even could be fatal
- Saves money for retirees and their insurance trust
- Uses DNA testing to help doctors making treatment decisions
- Results help make sure medications are beneficial from the start
- Avoids traditional trial-and-error process without DNA information







LIFE SCIENCES

"I received a call from a TRS member who had participated in the DNA testing program with her spouse. The spouse had a **heart attack earlier in the year** and was being discharged on **Clopidogrel**. They called to check this against his DNA results and found out **Clopidogrel would have been ineffective**.

The Pharmacist worked with the patient and his doctor to get an **effective medication**. Had the patient not called, there would be a high **likelihood of a readmission and recurrence of future heart attack**.

Not only did this preventive action dramatically affect the member's **quality of life**, but it also **prevented the costs of hospital admission** and **downstream costs** surrounding heart attack treatment and recovery."

KYRx team member

KEHP

MEHP

Personalized Medicine

Genetic Testing Wellness Program Gets National Attention

Journal of Precision Medicine





Personalized Medicine

Peer-Reviewed Initial Results Receive Attention



- 66% had genetic risks detected in a current medication
- 14.9% reduction in inpatient visits
- 6.8% reduction in emergency room visits
- \$37 million savings in direct medical charges over 32 months

KEHP MEHP

Personalized Medicine

Peer-Reviewed Initial Results Receive Attention



- \$37 million savings in direct medical charges over 32 months
- 66% had genetic risks detected in a currently prescribed medication
- 14.9% reduction in inpatient visits
- 6.8% reduction in emergency room visits
- \$218 savings a month per member, which equates to \$7,000 a member
- Return on investment of about 1,422%

Case Study: > 10,000 Program Participants



- More than 10,000 MEHP members enrolled (24.6%)
- Retrospective Review of medical claims for those with both 12 months of claims history prior to the program start and 32 months post program start
- N=5,288 participants compared to
- N=22,357 controls

| Variables | Intervention | Control |
|--------------------------------------|--------------|--------------|
| | (n = 5,288) | (n = 22,357) |
| Age in years, avg (SD) | 73.7 (5.7) | 74.0 (6.2) |
| 65-74, n (%) | 3,249 (61%) | 13,382 (60%) |
| 75-84 | 1,696 (32%) | 6,849 (31%) |
| >=85 | 343 (6%) | 2,126 (10%) |
| Sex, n (%) | | |
| Female | 3,523 (67%) | 14,893 (67%) |
| Male | 1,765 (33%) | 7,464 (33%) |
| Charlson Comorbidity Index, avg (SD) | 3.6 (1.4) | 3.6 (1.5) |
| 0-2, n (%) | 1,113 (21%) | 4,789 (21%) |
| 3-4 | 3,144 (59%) | 13,056 (58%) |
| 5+ | 1,031 (19%) | 4,512 (20%) |
| Number of Medications, avg (SD) | 13.0 (8.4) | 11.9 (8.3) |
| 0, n (%) | 79 (1%) | 584 (3%) |
| 1-2 | 223 (4%) | 1,281 (6%) |
| 3-4 | 429 (8%) | 1,997 (9%) |
| 5-7 | 786 (15%) | 3,788 (17%) |
| 8-10 | 904 (17%) | 3,703 (17%) |
| 11+ | 2,867 (54%) | 11,004 (49%) |

Jarvis, J.P., et al. (2021). *Real-world impact of a pharmacogenomics-enriched comprehensive medication management program.* Manuscript submitted for publication.

Case Study: Program Results




| Claim Type | Reduction |
|----------------------|-----------|
| Outpatient | 1.9% |
| Emergency Department | 6.8% |
| Inpatient | 14.9% |












Jarvis, J.P., et al. (2021). *Real-world impact of a pharmacogenomics-enriched comprehensive medication management program.* Manuscript submitted for publication.

Case Study: Cost Savings Achieved






Resulting PMPM cost avoidance of **\$218.82**

Per member cost savings at 32 months: \$7,002.24

Jarvis, J.P., et al. (2021). *Real-world impact of a pharmacogenomics-enriched comprehensive medication management program.* Manuscript submitted for publication.

Case Study: Cost Savings Achieved





Resulting PMPM cost avoidance of **\$218.82**

Per member cost savings at 32 months: \$7,002.24

Cumulative cost savings at 32 months: **\$37M**

Jarvis, J.P., et al. (2021). *Real-world impact of a pharmacogenomics-enriched comprehensive medication management program.* Manuscript submitted for publication.



Personalized Medicine

How to Sign Up



MEHP enrollees can contact Coriell at 888-454-9024 or www.coriell.com/trs to request free DNA kit.



Non-Medicare KEHP enrollees can contact Coriell and use HRA funds to pay the cost.







Program Success

CORIELL.

Feedback Survey

- How was your experience enrolling in the program? 4.24/5
- How was your experience with the pharmacists at the KYRx Coalition?
 4.37/5
- Do you feel that the program was valuable to you? 4.14/5



KEHP MEHP

Personalized Medicine


Reaching Further After Success of Pharmacogenomics



Pharmacogenomics Fall 2017



Breast Cancer Index 2021



Looking at other personalized diagnostic tools for 2022

MEHP

Personalized Medicine

Early Results — Real Story

- TRS member was prescribed a blood thinner after having a stroke
- TRS member had a mini-stroke while on that blood thinner
- TRS member took the DNA test and results showed the member was a slow metabolizer of the blood thinner and it did not interact well with their stomach medicine
- The Know Your Rx pharmacist worked with the TRS member and doctor to change to a different blood thinner
- The member is doing well





If a medication is unsafe or won't work for you, wouldn't you want to know?



CONFIDENTIAL • Coriell Life Sciences • www.coriell.com

Professional Memberships: Have Heard the TRS Story





















STANDARDIZING LABORATORY PRACTICES IN PHARMACOGENOMICS













Key Players

Teachers' Retirement System of the State of Kentucky

- Gary L. Harbin, CPA
- Jane Cheshire Gilbert, CPA
- Grace H. Dotson
- Leeann Uebel
- Members
- Board of Trustees

Coriell Life Sciences

- Scott Megill
- Jennifer Ferrang
- Steve Kradel
- Paul Chernin

- Victoria Clements
- Shana Shterban
- Tonya Bell
- Jeffrey Shaman
- Revel Health

CORIELL.

Know Your Rx (KYRx) Coalition

- Lucy B. Wells, RPh
- · April Prather, PharmD, MS
- Gina Beanland, PharmD
- · Zachary Wilkerson, PharmD, MBA
- Richard Amos, Executive Director
- Full Team Support

Aon

- Curt Dame
- Aon Health Solutions
- Aon Health Analytics Solutions; Pharmacy Practice
- Aon U.S. Health Solutions

CONFIDENTIAL • Coriell Life Sciences • www.coriell.com

34



Our Members Come First!

800-618-1687

8 a.m. – 5 p.m. ET Monday – Friday

info@trs.ky.gov https://trs.ky.gov

Protecting & Preserving Teachers' Retirement Benefits



Humana Group Medicare Advantage


Kentucky Public Pensions Authority
CERS/ KRS Retiree Health Plan
Committee Meeting
May 19, 2022











Agenda

- 01 | 2021 Plan Performance
- 02 | 2021 KPPA Stars Review
- 03 | McClennan Pilot Results
- 04 Introducing Centerwell

Humana.


2021 Plan Performance

Presented by Tracey Garrison



Premium Plan

Executive Summary All Trusts



Proprietary and Confidential


4

Premium Plan

Executive Summary by Trust

| Premium Plan | All Members | | | KRS/SPRS Members | | | CERS Members | | |
|-------------------------------|-------------|------------|--------|------------------|------------|---------|--------------|------------|--------|
| Fremidiii Fiaii | Current | Prior | Change | Current | Prior | Change | Current | Prior | Change |
| Prescriptions PMPM | 3.29 | 3.36 | -2.10% | 3.28 | 3.36 | -2.4% | 3.29 | 3.36 | -1.90% |
| Specialty % of Rx Net Paid | 38.5% | 37.1% | 1.40% | 40.20% | 38.90% | 1.30% | 37.00% | 35.50% | 1.50% |
| Member Cost Share | 6.50% | 6.70% | -0.20% | 6.50% | 6.60% | -0.10% | 6.50% | 6.70% | -0.20% |
| Large Claimant Spend Impact | 21.90% | 21.70% | 0.20% | 22.20% | 23.20% | -1.00% | 21.70% | 20.40% | 1.30% |
| Health Alerts Full Compliance | 57.20% | 64.00% | -6.8% | 57.70% | 64.60% | -6.90% | 56.80% | 63.50% | -6.70% |
| Mbrs w/ Preventative Services | 74.10% | 71.50% | 2.60% | 73.70% | 70.60% | 3.10% | 74.40% | 72.20% | 2.20% |
| Silver Sneakers Participation | 8.90% | 11.60% | -2.70% | 9.50% | 12.50% | -3.00% | 8.30% | 11.00% | -2.70% |
| Medical Admits/1000 | 170 | 182 | -6.70% | 164 | 182 | -10.30% | 175 | 182 | -3.80% |
| PMPM | \$1,365.86 | \$1,280.29 | 6.70% | \$1,370.90 | \$1,309.19 | 4.70% | \$1,362.10 | \$1,256.97 | 8.40% |
| Average Membership | 53,191 | 51,937 | 2.40% | 23,656 | 23,262 | 1.70% | 29,517 | 28,654 | 3.00% |

Essential Plan Executive Summary All Trusts



Essential Plan

Executive Summary by Trust

| Essential Plan | All Members | | KRS/SPRS Members | | | CERS Members | | | |
|-------------------------------|-------------|----------|------------------|----------|----------|--------------|----------|----------|--------|
| | Current | Prior | Change | Current | Prior | Change | Current | Prior | Change |
| Prescriptions PMPM | 2.31 | 2.35 | -1.80% | 2.16 | 2.24 | -3.10% | 2.39 | 2.42 | -1.00% |
| Specialty % of Rx Net Paid | 46.60% | 44.50% | 2.10% | 49.60% | 41.60% | 8.00% | 44.90% | 46.10% | -1.20% |
| Member Cost Share | 9.20% | 9.40% | -0.20% | 10.00% | 9.70% | 0.30% | 8.80% | 9.30% | -0.50% |
| Large Claimant Spend Impact | 17.90% | 22.50% | -4.60% | 14.00% | 20.40% | -6.40% | 19.90% | 23.60% | -3.70% |
| Health Alerts Full Compliance | 55.90% | 60.10% | -4.20% | 55.80% | 61.50% | -5.70% | 55.90% | 59.30% | -3.40% |
| Mbrs w/ Preventative Services | 69.70% | 66.50% | 3.20% | 69.10% | 66.10% | 3.00% | 70.00% | 66.60% | 3.40% |
| Silver Sneakers Participation | 9.10% | 12.10% | -3.00% | 10.40% | 11.90% | -1.50% | 8.40% | 12.20% | -3.80% |
| Medical Admits/1000 | 146 | 163 | -10.50% | 124 | 154 | -19.50% | 158 | 168 | -5.60% |
| РМРМ | \$879.36 | \$808.02 | 8.80% | \$806.52 | \$780.67 | 3.30% | \$921.44 | \$823.57 | 11.90% |
| Average Membership | 5,213 | 5,183 | 0.60% | 1,876 | 1,848 | 1.50% | 3,329 | 3,328 | 0.00% |

Dental Benefit Utilization 2021


| Members Utilizing: | 10,387 |
|--------------------|--------|
| Total Procedures: | 28,464 |

| Category | Procedure | Procedure Count | |
|------------|------------------------|------------------------|--|
| PREVENTIVE | FLUORIDE TREATMENTS | 12 | |
| | LAB & OTHER DIAG TESTS | 4 | |
| | ORAL EXAMS | 9,871 | |
| | OTHER PREVENTIVE | 3 | |
| | PROPHYLAXIS | 8,772 | |
| | X-RAYS | 6,271 | |
| MAJOR | BRIDGES | 3 | |
| | DENTURES | 2 | |
| | IMPLANT SERVICES | 1 | |
| | INLAYS AND CROWNS | 24 | |
| | OTHER PROSTHETICS | 1 | |
| BASIC | ANESTHESIA | 27 | |
| | ENDODONTICS | 1 | |
| | ORAL SURGERY | 1 | |
| | PERIODONTICS | 28 | |
| | RESTORATIONS | 3,436 | |
| | SIMPLE EXTRACTIONS | 6 | |
| OTHER | DRUGS | 1 | |

| Deductible and Annual Maximum Benefit | |
|--|---------|
| Deductible | \$0 |
| Annual Maximum Benefit | \$1,000 |
| Covered Dental Services | |
| Periodic Oral Exam – One Per Year | \$0 |
| Bitewing X-Rays – One Set Per Year | \$0 |
| Prophylaxis (Cleaning) – One Per Year | \$0 |
| Restorations (Fillings) – One Per Year | 50% |

2021 KPPA Stars Review

Presented by Andrea Biesel




Stars Category Breakdown

Healthcare Effectiveness Data and Information Set - Staying Healthy- Preventive Screenings

> Independent Review Entity-Appeals

(S) Improvement

Health plan improvement rates year over year



Centers for Medicare & Medicaid Services Complaints

CAHPS

Consumer Assessment of Healthcare Providers and Systems- Member Experience

Patient Safety


Drug safety & medication adherence

HOS

Health Outcomes Survey

10

KPPA 2021 HEDIS performance



2021 HEDIS measure highlights



CBP
Controlling Blood
Pressure



MRP
Medication Reconciliation
Post-discharge



Insights

Performance increases can be attributed to:

- Major advancements in data connections in 2021, specifically with Baptist
- Targeted outreaches with local provider groups around MRP

Proprietary and Confidential

12




Presented by Andrea Biesel




Stars Pilot Program with McClennan Group

- Humana Stars department partnered with the McClennan Group to pilot a health profile program to learn more about Group Medicare member's health goals and motivations.
- Objectives: Deeper understanding of our Group Medicare members, development of more personalized outreach specific to their health needs, and increased adherence to enable better health outcomes.



Example user path





McClennan Program Highlights: KPPA Members

55.9% Reach rate

1,451

KPPA members opted into the program 404 via email, 1047 via text messaging

KPPA engaged members

Individual tracks(health content/activities) completed by engaged members



McClennan Program Highlights: KPPA Member Profiles



Social

204 KPPA members (28.5%)

- I want to be Healthy, Happy and Loved
- They prioritize their friendships and other relationships, and they desire to be loved and bring joy to others.
- Potential Tones: charismatic, unexpected
 & witty, helpful



Active

256 KPPA members (35.8%)

- I want to be Healthy, Active and Happy
- This group prioritizes an active lifestyle and independence. They have a stronger interest in the outdoors and impacting the environment than any other group.
- Potential Tones: focused & punchy, simple & straightforward, unassuming & down-to-earth



Spiritual

255 KPPA members (35.7%)

- I want to be Healthy, Happy and Active
 - Most interested in their faith and spirituality. They want to have an impact on their spiritual group and the less fortunate.
 - Potential Tones: philosophical, lighthearted

Proprietary and Confidential

Over **500** KPPA members' top goal was "I want to be healthy"

Introducing Centerwell

Presented by Tracey Garrison



CenterWell Overview: A holistic approach to care



Home Care

Individualized care, centered in the comfort of your home whenever you need it





Primary Care

Truly personalized primary care that understands and treats the whole, unique you at the center

formerly Partners in Primary Care.

Pharmacy

Pharmacy services delivered with clinical expertise and care centered on your unique needs

formerly



19

Proprietary and Confidential

The CenterWell name reflects

Humana's commitment to putting the

people we serve at the center of

everything we do and focusing on

CenterWell will be used to describe

health care service offerings. The

the organization's core health plan

and insurance capabilities.

and connect a range of the company's

Humana brand continues to represent

their unique needs so they can

achieve their best health.

CenterWell Business Segments

Overarching brand



Business segments

Brand launch

Type of care service or product

Senior Primary Care

April 5, 2021

Senior-focused, value-based primary care clinics in:

60 locations 9 States **Home Health**

Mar. 1, Jun. 1, Sept. 1 2022

Formerly Kindred at Home, inhome skilled care provided by nurses and therapists present in:

350 locations 38 states 6 Kentucky locations **Pharmacy**

Go Live June 10, 2022

Formerly Humana Pharmacy:

Traditional mail-order Specialty Pharmacy Over-the-counter meds Retail locations

20

Humana Pharmacy and Humana Specialty Pharmacy Awareness Campaigns

Wave 1 Communications

- Targeting middle to end of March to hit homes
- Any member with Humana Pharmacy and/or Humana Specialty Pharmacy claims in the last 180 days will be included in campaign
- Postcards, emails, digital ads, and interact messages

Wave 2 Communications

- Targeting the third week of April
- Same criteria as Wave 1 for campaign inclusion
- Emails and digital ads

Wave 3 Communications

- Targeting the third week of May
- Same criteria as other waves for inclusion
- Letter, emails, digital ad, interact messages

Thank you!

Tracey Garrison
Humana Group Medicare
Senior Account Executive
E-Mail tgarrison@humana.com



Glossary of Terms

PMPM – Per Member Per Month

PDP – Prescription Drug Plan

MA – Medicare Advantage Plan

MAPD – Medicare Advantage Prescription Drug Plan

ASO Fee – Administrative Services Only Fee

MRA – Medicare Risk Adjustment

YTD - Year to Date


YOY – Year Over Year

CMS – Centers for Medicare & Medicaid Services

MOOP – Maximum Out of Pocket

MER – Medical Expense Ratio (revenue/claims)

TrOOP – True Out of Pocket Maximum



Pharmacogenomics April 2022

What is Pharmacogenomics?

The study of how genes influence individuals' responses to drug treatments.



 This is a dynamic, evolving area of medicine which is monitored by Humana's Integrated Health Solutions and Patient Safety Clinical Programs Teams.

2022 Medicare Coverage

- CMS does not cover pharmacogenomics tests for predictive purposes or broad panel testing.
 - Predictive testing is considered "screening" when a member has no signs or symptoms.
 - Broad panel tests look for variations in multiple genes affecting a wide array of medications.
 - Single gene tests are more focused and look for genetic interactions between specific genes and medications.
- ✓ CMS does cover single drug-gene testing for some medications when medically necessary.
 - Example:
 - According to FDA approved labeling for seizure medications such as carbamazepine (Tegretol) and phenytoin (Dilantin), genetic testing should be done for patients with Asian ancestry.
 - Populations in Southeast Asia have a higher risk for potentially life-threatening skin conditions that may result from these medications due to the presence of a particular gene/genetic mutation.
 - Covered testing must be ordered by a physician or qualified non-physician practitioner.
 - Member-initiated tests frequently advertised online or on TV are not covered by Medicare.

Humana Pharmacogenomics Pilot

- Humana is currently conducting a pilot of MAPD Individual members.
- Pilot Objectives
 - Evaluate the value of genetic testing to guide therapy decisions
 - Evaluate impact on longer term outcomes such as medication adherence, hospital admissions, readmissions, and cost of care
 - · Determine if the process should be expanded on a larger scale and applied to additional markets
- Results will be evaluated in late 2022 or early 2023 to determine if outcomes and return on investment support a larger rollout.



KENTUCKY PUBLIC PENSIONS AUTHORITY

David L. Eager, Executive Director 1260 Louisville Road • Frankfort, Kentucky 40601 kyret.ky.gov • Phone: 502-696-8800 • Fax: 502-696-8822



To: Retiree Health Plan Committee

From: Connie Pettyjohn

Division Director - Retiree Health Care

Date: May 19, 2022

Subject: Medicare Advantage Request for Proposal

Kentucky Public Pensions Authority (KPPA) is required under Kentucky Revised Statute 45A, the Kentucky Model Procurement Code, to elicit a request for proposal (RFP) for the Procurement of the Medicare Advantage insurance plans. The current contract for the Medicare eligible health insurance plans has no more renewals, so KPPA posted an RFP for these services to be effective for calendar year 2023. As allowed under the procurement code, the KPPA procurement team notified as many potential vendors as we are aware of, including all that are registered with the Commonwealth of Kentucky.

Please reference the table below for an anticipated timeline for the RFP:

| Milestone | Anticipated Date |
|--|-------------------|
| Release of RFP | February 23, 2022 |
| Written Questions due by: 4:30 pm Eastern Time | March 10, 2022 |
| Anticipated Commonwealth Response to Written Questions | March 14, 2022 |
| (KPPA returned responses to Finance on 3/23/22) | |
| Commonwealth Response to Written Questions | April 4, 2022 |
| Written Questions 2nd round due by: 4:30 pm Eastern Time | April 20, 2022 |
| Proposals Due by: 3pm Eastern Time | May 5, 2022 |
| Proposals Sent to KPPA for Review | May TBD, 2022 |
| Anticipated Contract Award | June 1-15, 2022 |

No Action Needed: This memo is for information purposes only.